VALN

What one share of Valneva SE holds

Biological Products, (No Diagnostic Substances)

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best-, or only-in-class vaccine solutions.

Valneva SE’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.

Per-share figures
Sales$2.35
Profit−$1.55
Capex (buildings and equipment)$0.06
Free cash flow−$0.77
Cash and investments$1.48
Debt$2.42
Book value$1.44

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2020$2.77−$1.62$0.48$2.99—$2.08
2022$6.59−$2.61$0.53−$5.01—$3.40
2023$2.40−$1.58$0.22−$3.39—$2.04
2024$2.52−$0.18$0.21−$1.20—$2.31
2025$2.35−$1.55$0.06−$0.77—$1.44

Common questions about Valneva SE

How much does one share of Valneva SE earn?

Over its latest fiscal year, Valneva SE lost $1.55 for each share on $2.35 of sales.

Does Valneva SE pay a dividend?

Valneva SE didn’t pay a dividend over its latest fiscal year, according to its SEC filings.

What is Valneva SE’s book value per share?

Valneva SE’s book value is $1.44 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.

How much cash and debt does each share of Valneva SE have?

Each share of Valneva SE has $1.48 of cash and investments and $2.42 of debt, as of December 31, 2025.

What is Valneva SE’s free cash flow per share?

−$0.77 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.

Has Valneva SE bought back shares?

Valneva SE’s share count rose about 85% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.